866-997-4948(US-Canada Toll Free)

Systemic Lupus Erythematosus - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 409 Pages

Systemic Lupus Erythematosus - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 26, 28, 1, 44, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Systemic Lupus Erythematosus - Overview 7
Systemic Lupus Erythematosus - Therapeutics Development 8
Systemic Lupus Erythematosus - Therapeutics Assessment 24
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 38
Systemic Lupus Erythematosus - Drug Profiles 78
Systemic Lupus Erythematosus - Dormant Projects 379
Systemic Lupus Erythematosus - Discontinued Products 384
Systemic Lupus Erythematosus - Product Development Milestones 386
Appendix 395

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H1 2017
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H1 2017
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H1 2017
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2017
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H1 2017
Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H1 2017
Systemic Lupus Erythematosus - Pipeline by Celldex Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H1 2017
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2017
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2017
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2017
Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2017
Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Kadmon Corp LLC, H1 2017
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2017
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H1 2017
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2017
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2017
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2017
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2017
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2017
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2017
Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2017
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Shire Plc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H1 2017
Systemic Lupus Erythematosus - Pipeline by TxCell SA, H1 2017
Systemic Lupus Erythematosus - Pipeline by UCB SA, H1 2017
Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H1 2017
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
Systemic Lupus Erythematosus - Dormant Projects, H1 2017
Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..1), H1 2017
Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..2), H1 2017
Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..3), H1 2017
Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..4), H1 2017
Systemic Lupus Erythematosus - Discontinued Products, H1 2017
Systemic Lupus Erythematosus - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *